During their development, babies who will be born with Down syndrome have higher levels of anti-angiogenic factors in their lungs, impairing fetal…
Articles by Patricia Inácio, PhD
People with pulmonary arterial hypertension (PAH) have higher than usual levels of a protein produced in cells in response to…
Low-risk pulmonary arterial hypertension (PAH) patients may be able to switch from pump-infusion parenteral prostacyclin therapy to more convenient oral therapies, according to the study,…
A prospective analysis of two clinical trials, PATENT-1 and PATENT-2, showed that riociguat (Adempas) treatment improves several parameters of lung and…
The delivery and efficiency of ethyl pyruvate (EP), an anti-inflammatory and anti-oxidant agent, was significantly improved in a rat model…
A drug approved for a genetic condition called urea cycle disorder — sodium 4-phenylbutyric acid (4-PBA) — shows a protective effect for pulmonary…
Riociguat treatment administered at steady state (2.5 mg, three times a day) to women with pulmonary arterial hypertension (PAH) did not…
A microRNA, called miR-214, promotes excessive cellular proliferation in pulmonary arterial hypertension (PAH), and decreasing its expression may significantly impair phenotype changes…
Monotherapy given to patients with congenital heart defects associated with pulmonary arterial hypertension, or PAH-CHD, improved their exercise capacity more than a combined therapy,…
Researchers recently investigated the link between thyroid gland function and idiopathic pulmonary hypertension, finding subclinical hypothyroidism in almost half of patients observed. The…
People with chronic thromboembolic pulmonary hypertension (CTEPH) show an increased prevalence of sleep disordered breathing, a condition predicted by low cardiac…
Galectin-3 (Gal-3) and the hormone aldosterone are two potential biomarkers for disease progression in patients with pulmonary arterial hypertension, according to a…